Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 133

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 133
---
 amortization of prepaid contracts of
$54,612, an increase of $642,329 in stock-based compensation, partially offset a decrease of $2,334,064 in Net Loss.

Net Cash Used in Investing Activities:

No net cash was provided by
or used in investing activities during the years ended December 31, 2024 and 2023.

Net Cash Provided by Financing Activities:

Net cash provided by financing
activities for the year ended December 31, 2024 increased by $7,207,036 from the year ended December 31, 2023. The increase is mainly
attributed the proceeds raised from the Company’s initial public offering, net of offering costs of $9,725,213 partially offset
by the repayments of notes payables of $2,361,677.

Off-balance sheet financing arrangements

We have no obligations, assets
or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships
with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established
for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements,
established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

We have no off-balance sheet
arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Business Development Activities

The Company initiated business
development activities in the Asian region in 2021. The Company has a strong strategic interest in accelerating the drug development
and potential commercialization efforts of JOTROL™ in this market. Our Chairman & CEO, presented in person, our company’s
status and pipeline at the BIOHK 2023 conference in Hong Kong in September of 2023. The presentation led to several follow-on meetings,
and we have recently agreed to service agreements in the areas of business development, CMC (“Chemistry, Manufacturing, and Controls”),
regulatory affairs and clinical trial management. The Asian market is very large and hard to penetrate for a small company and we believe
that our strategy with these agreements is cost effective and have the possibility to accelerate an out-licensing deal in the South-East
Asian territories. However, there are no assurances that this approach